The short-term follow-up precluded a conclusion of statistically significant benefits from the shortening of the transportation and door-to-needle time.”
“Norwegian national policies have been distinguished by their focus on equity, contributing to comprehensive policies to reduce the social inequities in health(SIH). The-newly-adopted Public health act, which aims at reducing the SIH, endorses these acknowledgements while highlighting the importance of municipalities as the key actors in public health. Municipal obligations include inter-sectoral policies for health, health impact assessments (HIA), and the development of local health overviews. Against the background

of a system of local autonomy in Norway, this article illuminates whether, and how, municipal public health policies reflect national

priorities. Our data are based on one qualitative study, combining document content analysis and expert Selleckchem LDK378 interviews conducted in 2011, and one quantitative questionnaire sent to municipal chief administrative officers in 2011. Our ABT-263 order findings indicate a divide between national and municipal public health strategies. Many municipalities focus on life-style and health-care related measures. Only few municipalities acknowledge the social determinants of health and have implemented HIA and health overviews. Arguing for the importance of concerted multi-level action to reduce the SIH, we need to better understand the gap between national and municipal approaches. We thus suggest further research to illuminate the challenges and success factors faced at local levels. (C) 2013 Elsevier Ireland Ltd. All rights reserved.”
“Objectives: To review the reporting of key items of recruitment information in trial reports and estimate the number needed to screen to recruit one additional participant.

Study Design and Setting: Review of breast cancer trials published in the years 2003-2005, 2007, and 2008.

Results:

The search identified 1,570 potentially Volasertib eligible studies. After a random selection of 20% from each year and checking against inclusion criteria, a total of 207 studies were included in the review. Some items of information were well reported, such as the number included in the analysis. Sample size calculations were often not presented, but reporting is slowly improving. Who recruits participants and how many individuals were screened are often not reported. The median number needed to screen to recruit one additional participant was two (range, 1-593).

Conclusions: Without reporting the when, where, by whom, and how many of recruitment, trialists deny readers part of the contextual description they need to judge whether a trial’s results are applicable to their own situation. Trialists and journal editors need to be more diligent in following the reporting recommendations of the Consolidated Standards of Reporting Trials statement. (C) 2011 Elsevier Inc. All rights reserved.